Tocilizumab prescribing criteria for COVID-19 patients

doi:10.1080/21645515.2020.1822137

Observational Study

. 2021 Apr 3;17(4):1128.

doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.

Tocilizumab prescribing criteria for COVID-19 patients

Ayman M Al-Qaaneh^{1

2}, Fuad H Al-Ghamdi¹

Affiliations

¹ Clinical Pharmacy Services Division, Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran, Saudi Arabia.
² Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.

PMID: 33079613
PMCID: PMC8018477
DOI: 10.1080/21645515.2020.1822137

Observational Study

Tocilizumab prescribing criteria for COVID-19 patients

Ayman M Al-Qaaneh et al. Hum Vaccin Immunother. 2021.

. 2021 Apr 3;17(4):1128.

doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.

Authors

Ayman M Al-Qaaneh^{1

2}, Fuad H Al-Ghamdi¹

Affiliations

¹ Clinical Pharmacy Services Division, Pharmacy Services Department, Johns Hopkins Aramco Healthcare (JHAH), Dhahran, Saudi Arabia.
² Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.

PMID: 33079613
PMCID: PMC8018477
DOI: 10.1080/21645515.2020.1822137

No abstract available

Keywords: COVID-19; SARS-CoV-2; Tocilizumab; cytokine storm; interleukin 6; monoclonal antibody.

PubMed Disclaimer

Cited by

Comparative Study of Cytokine Storm Treatment in Patients with COVID-19 Pneumonia Using Immunomodulators.
Marc F, Moldovan CM, Hoza A, Magheru S, Ciavoi G, Farcas DM, Sachelarie L, Calin G, Romila L, Damir D, Naum AG. Marc F, et al. J Clin Med. 2022 May 23;11(10):2945. doi: 10.3390/jcm11102945. J Clin Med. 2022. PMID: 35629072 Free PMC article.
Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study.
Al-Qaaneh AM, Al-Ghamdi FH, AbdulAzeez S, Borgio JF. Al-Qaaneh AM, et al. Pharmaceutics. 2022 Mar 11;14(3):624. doi: 10.3390/pharmaceutics14030624. Pharmaceutics. 2022. PMID: 35335998 Free PMC article.

References

1. Hu B, Huang S, Yin L.. The cytokine storm and COVID-19. J Med Virol. 2020. [2020 June28]. doi:10.1002/jmv.26232. - DOI - PMC - PubMed
1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm‘ in COVID-19. J Infect. 2020. [2020 April14];80(6):607–13. doi:10.1016/j.jinf.2020.03.037. - DOI - PMC - PubMed
1. Meftahi G, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”. Inflamm Res. 2020. [2020 June13]:1–15. doi:10.1007/s00011-020-01372-8. - DOI - PMC - PubMed
1. Lakatos B, Gopcsa L, Gondos E, Riczu A, Várnai Z, Nagy É, Molnár E, Bekő G, Bobek I, Reményi P, et al. [Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of TTocilizumab in Hungary at a department of infectology]. Orv Hetil. 2020. [2020 June17];161:1070–77. doi:10.1556/650.2020.31899. - DOI - PubMed
1. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020. [2020 April8];92(7):814–18. doi:10.1002/jmv.25801. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Hu B, Huang S, Yin L.. The cytokine storm and COVID-19. J Med Virol. 2020. [2020 June28]. doi:10.1002/jmv.26232. - DOI - PMC - PubMed

[2] Hu B, Huang S, Yin L.. The cytokine storm and COVID-19. J Med Virol. 2020. [2020 June28]. doi:10.1002/jmv.26232. - DOI - PMC - PubMed

[3] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm‘ in COVID-19. J Infect. 2020. [2020 April14];80(6):607–13. doi:10.1016/j.jinf.2020.03.037. - DOI - PMC - PubMed

[4] Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm‘ in COVID-19. J Infect. 2020. [2020 April14];80(6):607–13. doi:10.1016/j.jinf.2020.03.037. - DOI - PMC - PubMed

[5] Meftahi G, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”. Inflamm Res. 2020. [2020 June13]:1–15. doi:10.1007/s00011-020-01372-8. - DOI - PMC - PubMed

[6] Meftahi G, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”. Inflamm Res. 2020. [2020 June13]:1–15. doi:10.1007/s00011-020-01372-8. - DOI - PMC - PubMed

[7] Lakatos B, Gopcsa L, Gondos E, Riczu A, Várnai Z, Nagy É, Molnár E, Bekő G, Bobek I, Reményi P, et al. [Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of TTocilizumab in Hungary at a department of infectology]. Orv Hetil. 2020. [2020 June17];161:1070–77. doi:10.1556/650.2020.31899. - DOI - PubMed

[8] Lakatos B, Gopcsa L, Gondos E, Riczu A, Várnai Z, Nagy É, Molnár E, Bekő G, Bobek I, Reményi P, et al. [Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of TTocilizumab in Hungary at a department of infectology]. Orv Hetil. 2020. [2020 June17];161:1070–77. doi:10.1556/650.2020.31899. - DOI - PubMed

[9] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020. [2020 April8];92(7):814–18. doi:10.1002/jmv.25801. - DOI - PMC - PubMed

[10] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020. [2020 April8];92(7):814–18. doi:10.1002/jmv.25801. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Tocilizumab prescribing criteria for COVID-19 patients

Affiliations

Tocilizumab prescribing criteria for COVID-19 patients

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous